Streetwise Reports' Article Archives — February 2022 back to current month (18)
Biotech to Take Novel Cancer Drug to Market in H1/22 (02/28/2022)
This biotech company is commercializing its lead drug candidate, Kimmtrak, has a catalyst-rich 2022, and has various clinical-stage drugs for cancers and autoimmune and infectious diseases.
A promising biotech company is finding new ways to treat neurodegenerative diseases by focusing on misfolded proteins.
Pharma Co. Posts 364% YOY Revenue Increase in Q421 (02/25/2022)
Aerie Pharmaceuticals Inc. shares traded 30% higher after the ophthalmology-focused pharmaceutical company reported Q4/21 and FY/21 financial results and announced the appointment of a new Chief Medical Officer.
Lantheus Holdings Inc. shares traded to a new 52-week high after the firm reported Q4/21 and FY/21 financial results that included a 25.3% increase in annual revenue. The firm also advised that the FDA approved the sNDA for its isolator-based drug manufacturing facility for diagnostic ultrasound enhancing agent DEFINITYŽ for patients in the U.S. with suboptimal echocardiograms.
Q1 Results of Cannabis Firm Down YoY (02/24/2022)
Despite a dampened Q1 FY22 performance and an uncertain future, parts of a cannabis firm's story remain attractive, warranting a Market Perform rating, noted a Noble Capital Markets report.
Shares of Beauty Health Co. traded 32% higher after the company that is credited with creating the category of hydradermabrasion reported Q4/21 and FY/21 financial results outlining significant improvements in sales, margins and adjusted earnings.
Shares of a health care professional staffing and services company traded 12% higher after the company reported Q4/21 financial results that included a 116% YoY increase in revenue and a 1,149% YoY increase in net income.
Whereas U.S. multistate cannabis operators are expected to do well in 2022, federal legalization of cannabis would give a jolt to companies of all sizes, noted a ROTH Capital Partners report.
Pharma Co. Decreases BMI by 14.3% in Obesity Trial (02/18/2022)
Shares of this pharmaceutical company traded 16% higher after it reported positive interim data from its long-term extension study of a treatment for obesity and hyperphagia in patients with Bardet-Biedl Syndrome (BBS).
Dialysis Equip. Co. Posts Record FY21 Sales (02/17/2022)
Shares of a wireless mobile dialysis equipment maker traded 15% higher after the company reported FY/21 financial results highlighting a 105% YoY increase in revenue to $102.6 million.
Small-Cap Drug Co. Fights Clinicians' COVID Stress (02/15/2022)
In a recent interview with Streetwise Reports, Cybin Inc.'s General and IP Counsel Robert Mino explained the company's position at the forefront of mental health treatment via psychedelics. "This sector has the potential to improve the human condition on a massive scale."
Shares of BioDelivery Sciences International Inc. traded 52% higher after the company reported that it agreed to be acquired by Collegium Pharmaceutical Inc. in an all-cash deal for $5.60 per share.
Canadian Hedge Fund CIO Talks Top 2022 Prospects (02/09/2022)
AlphaNorth Asset Management was recently recognized with multiple performance awards at the 2021 Alternative IQ Canadian Hedge Fund Awards. The AlphaNorth Partners Fund won first place for its five-year annualized return gaining 40.35% for the period. The fund also placed second for its three-year return and third for its one-year return. Streetwise Reports sat down with CIO Steven Palmer to discuss some of the firm's recent investments and emerging opportunities for 2022.
Mental Health Co. Brings Psychedelics to the World (02/09/2022)
In Citi's Jan. 25, 2022 Psychedelic Call Series broadcast, Novamind CEO Yaron Conforti and Chief Medical Officer Dr. Reid Robison discussed how the company is increasing people's access to psychedelic therapies for mental health disorders.
Doximity Inc. shares traded 25% higher after the digital medical platform provider used by 80% of all physicians in the U.S. reported Q3/22 financial results that included a 67% YoY increase in revenue.
In a phase 2 clinical study, Todos Medical's oral antiviral Tollovir showed a 100% reduction in mortality from COVID-19.
Algernon Pharmaceuticals plans to be the world's first company to test the psychedelic drug DMT in stroke patients, and it's close to achieving its goal.
Drug Re-Purposing Co. Pursues Novel Stroke Therapies (02/03/2022)
Drug re-purposing co. Algernon Pharmaceuticals Inc. is actively reinventing itself. The firm's leading therapeutic candidate NP-120 (Ifenprodil) is currently being evaluated in a Phase 2 trial for IPF and chronic cough, and the company is now moving forward with a revolutionary new use for DMT to treat ischemic stroke.
|"Data presented by peers at the CTAD conference are relevant to PMN."|